

# Geke A P Hospers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3855020/publications.pdf>

Version: 2024-02-01

153  
papers

9,005  
citations

76294

40  
h-index

46771

89  
g-index

155  
all docs

155  
docs citations

155  
times ranked

11446  
citing authors

#	ARTICLE	IF	CITATIONS
1	<sup>18</sup> F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 899-905.	2.8	36
2	Discontinuation of anti-PD-1 monotherapy in advanced melanoma: Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326.	2.3	12
3	The unfavorable effects of COVID-19 on Dutch advanced melanoma care. <i>International Journal of Cancer</i> , 2022, 150, 816-824.	2.3	18
4	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	15.2	158
5	Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases. <i>BMC Cancer</i> , 2022, 22, 247.	1.1	3
6	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 167, 70-80.	1.3	19
7	Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer: The RAPIDO trial. <i>Radiotherapy and Oncology</i> , 2022, 171, 69-76.	0.3	20
8	Clinical Validity of <sup>18</sup> F-Fluoro-17 $\beta$ -Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3642-3652.	0.8	21
9	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	15.2	121
10	Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9546-9546.	0.8	0
11	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. <i>Melanoma Research</i> , 2022, 32, 460-468.	0.6	7
12	Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 9577-9577.	0.8	0
13	Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9501-9501.	0.8	12
14	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 29-42.	5.1	739
15	Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 144, 151-161.	1.3	13
16	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. <i>British Journal of Cancer</i> , 2021, 124, 1222-1230.	2.9	16
17	Abstract PS3-05: Value of [18F]-FES-PET to solve clinical dilemmas in breast cancer patients: A retrospective study. , 2021, , .		0
18	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. <i>Hepatology International</i> , 2021, 15, 510-519.	1.9	14

#	ARTICLE	IF	CITATIONS
19	Interpreting the RAPIDO trial: factors to consider – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e90-e91.	5.1	2
20	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
21	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 641-648.	2.0	46
22	Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible. <i>Annals of Surgical Oncology</i> , 2021, 28, 5194-5204.	0.7	9
23	Value of <sup>18</sup> F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1214-1220.	2.8	21
24	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2826.	1.7	11
25	Clinical selection strategy for and evaluation of intra-operative brachytherapy in patients with locally advanced and recurrent rectal cancer. <i>Radiotherapy and Oncology</i> , 2021, 159, 91-97.	0.3	1
26	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4369-4376.	3.3	23
27	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1995-2004.	0.8	291
28	OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era. <i>Neuro-Oncology Advances</i> , 2021, 3, iii14-iii14.	0.4	0
29	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1031-1038.	0.5	2
30	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. <i>Cancers</i> , 2021, 13, 4639.	1.7	9
31	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. <i>European Journal of Cancer</i> , 2021, 158, 234-245.	1.3	12
32	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 82-89.	0.6	2
33	Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 3951-3960.	0.7	10
34	Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. <i>Cancers</i> , 2021, 13, 5077.	1.7	1
35	Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer. <i>Diagnostics</i> , 2021, 11, 2019.	1.3	4
36	Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2021, 10, 8395-8404.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66.	0.6	6
38	Detection of Dural Metastases Before the Onset of Clinical Symptoms by $^{16}\alpha$ -[ $^{18}\text{F}$ ]Fluoro- $^{17}\beta$ -Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, e165-e167.	0.7	7
39	Quantitative fluorescence endoscopy: an innovative endoscopy approach to evaluate neoadjuvant treatment response in locally advanced rectal cancer. <i>Gut</i> , 2020, 69, 406-410.	6.1	37
40	Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 655-661.	2.8	34
41	Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. <i>European Journal of Cancer</i> , 2020, 126, 11-20.	1.3	39
42	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , 2020, 30, 261-267.	0.6	27
43	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	0.8	44
44	Image Quality and Interpretation of [ $^{18}\text{F}$ ]-FES-PET: Is There any Effect of Food Intake?. <i>Diagnostics</i> , 2020, 10, 756.	1.3	4
45	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , 2020, 5, e000945.	2.0	14
46	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. <i>European Journal of Cancer</i> , 2020, 137, 127-135.	1.3	14
47	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. <i>Cancers</i> , 2020, 12, 2072.	1.7	16
48	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. <i>Journal of Immunotherapy</i> , 2020, 43, 256-264.	1.2	17
49	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer $^{18}\text{F}$ -BMS-986192. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1839-1844.	2.8	37
50	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
51	Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 999-1013.	2.7	38
52	Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 235-246.	0.6	42
53	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	2.3	27
54	Application of PET Tracers in Molecular Imaging for Breast Cancer. <i>Current Oncology Reports</i> , 2020, 22, 85.	1.8	28

#	ARTICLE	IF	CITATIONS
55	Development and Evaluation of Interleukin-2â€‘Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1355-1360.	2.8	32
56	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer â€‘ Results of the international randomized RAPIDO-trial. <i>Radiotherapy and Oncology</i> , 2020, 147, 75-83.	0.3	132
57	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	1.7	15
58	Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. <i>EJNMMI Research</i> , 2020, 10, 40.	1.1	13
59	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10002-10002.	0.8	57
60	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4006-4006.	0.8	84
61	Surgery for unresectable stage IIIc and IV melanoma in the era of new systemic therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10032-10032.	0.8	0
62	Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients. <i>Acta OncolÃ³gica</i> , 2019, 58, 1640-1647.	0.8	7
63	Metastatic Uveal Melanoma: Treatment Strategies and Survivalâ€‘Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , 2019, 11, 1007.	1.7	22
64	Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 15.	1.8	15
65	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
66	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. <i>Oncology</i> , 2019, 8, 1558664.	2.1	0
67	O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS). <i>Ecological Management and Restoration</i> , 2019, 32, .	0.2	0
68	Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. <i>Journal of Immunotherapy</i> , 2019, 42, 208-214.	1.2	12
69	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019, 11, 1940.	1.7	29
70	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	1.3	13
71	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9605-TPS9605.	0.8	16
72	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	0.7	11

#	ARTICLE	IF	CITATIONS
73	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	0.7	11
74	Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. <i>Melanoma Research</i> , 2018, 28, 96-104.	0.6	41
75	<sup>18</sup> F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1212-1218.	2.8	45
76	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 925-933.	2.0	8
77	Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli et al. <i>Arthritis Care and Research</i> , 2018, 70, 1275-1275.	1.5	5
78	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 268-275.	0.8	91
79	Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative <sup>18</sup> F-FDG PET/CT analysis. <i>EJNMMI Research</i> , 2018, 8, 101.	1.1	18
80	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. <i>BMC Cancer</i> , 2018, 18, 877.	1.1	115
81	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018, 28, 326-332.	0.6	8
82	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017, 79, 176-184.	1.3	31
83	Synthesis and Evaluation of the Estrogen Receptor <sup>125</sup> I-Selective Radioligand 2- <sup>18</sup> F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with <sup>16</sup> I- <sup>18</sup> F-Fluoro-17 <sup>125</sup> I-Estradiol. <i>Journal of Nuclear Medicine</i> , 2017, 58, 554-559.	2.8	19
84	<sup>18</sup> F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, 612-614.	0.7	19
85	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165.	1.3	77
86	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1906-1912.	2.8	48
87	In Vivo Quantification of ER <sup>125</sup> Expression by Pharmacokinetic Modeling: Studies with <sup>18</sup> F-FHNP PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1743-1748.	2.8	6
88	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524.	0.8	17
89	Impact of current "insufficient" clinical nodal staging on treatment decisions and response to neoadjuvant chemoradiotherapy in esophageal cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 111-111.	0.8	0
90	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480

#	ARTICLE	IF	CITATIONS
91	Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. <i>Rheumatology</i> , 2016, 55, 1143-1145.	0.9	63
92	Recommendations and Technical Aspects of $^{16}\alpha$ -[ $^{18}\text{F}$ ]Fluoro- $^{17}\beta$ -Estradiol PET to Image the Estrogen Receptor In Vivo. <i>Clinical Nuclear Medicine</i> , 2016, 41, 844-851.	0.7	37
93	Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients. <i>American Journal of Surgery</i> , 2016, 212, 89-95.	0.9	1
94	Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. <i>Journal of Nuclear Medicine</i> , 2016, 57, 96S-104S.	2.8	8
95	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11553-11553.	0.8	2
96	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9526-9526.	0.8	2
97	Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma: The TRAP study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4142-TPS4142.	0.8	0
98	Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using $^{16}\alpha$ - $^{18}\text{F}$ -Fluoro- $^{17}\beta$ -Estradiol PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 50-55.	2.8	44
99	Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e133-e134.	0.8	10
100	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1090-1098.	5.1	1,861
101	Hormone receptors as a marker of poor survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 634-639.	0.6	43
102	CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 117, 152-158.	0.3	19
103	Positron emission tomography of tumour [ $^{18}\text{F}$ ]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1674-1681.	3.3	48
104	FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.. <i>Journal of Clinical Oncology</i> , 2015, 33, 527-527.	0.8	2
105	CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. <i>Current Pharmaceutical Design</i> , 2015, 21, 2276-2283.	0.9	15
106	Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 188-192.	0.3	18
107	Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy. <i>Annals of Surgery</i> , 2014, 260, 786-793.	2.1	134
108	Increased risk of thromboembolism in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. <i>American Journal of Surgery</i> , 2014, 208, 215-221.	0.9	26

#	ARTICLE	IF	CITATIONS
109	Impact of Neoadjuvant Chemoradiotherapy on Postoperative Course after Curative-intent Transthoracic Esophagectomy in Esophageal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2014, 21, 605-611.	0.7	52
110	Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 412.	2.2	38
111	Off-Label Prescription of Genetically Modified Organism Medicines in Europe: Emerging Conflicts of Interest?. <i>Human Gene Therapy</i> , 2014, 25, 893-896.	1.4	0
112	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58.	2.0	253
113	Residual Tumor After Neoadjuvant Chemoradiation Outside the Radiation Therapy Target Volume: A New Prognostic Factor for Survival in Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 845-852.	0.4	23
114	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444.	5.1	242
115	Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. <i>Radiotherapy and Oncology</i> , 2014, 112, 284-288.	0.3	40
116	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer â€” the RAPIDO trial. <i>BMC Cancer</i> , 2013, 13, 279.	1.1	237
117	Different Recurrence Pattern After Neoadjuvant Chemoradiotherapy Compared to Surgery Alone in Esophageal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2013, 20, 4008-4015.	0.7	43
118	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, e465-e475.	5.1	173
119	Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: Case report and review of the literature. <i>European Journal of Cancer</i> , 2013, 49, 3850-3855.	1.3	16
120	Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). <i>Acta OncolÃ³gica</i> , 2013, 52, 1786-1788.	0.8	67
121	Effect of vemurafenib on a V600R melanoma brain metastasis. <i>European Journal of Cancer</i> , 2013, 49, 1795-1796.	1.3	7
122	Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands. <i>Annals of Surgical Oncology</i> , 2013, 20, 1985-1992.	0.7	26
123	Molecular imaging for monitoring treatment response in breast cancer patients. <i>European Journal of Pharmacology</i> , 2013, 717, 2-11.	1.7	14
124	Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing. <i>Molecular Cancer Research</i> , 2013, 11, 1029-1039.	1.5	72
125	Abstract 4768: Frequency and prognostic value of hormone receptor expression in epithelial ovarian cancer.. , 2013, , .		2
126	Preoperative chemoradiotherapy (CRT) in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 89-89.	0.8	0



#	ARTICLE	IF	CITATIONS
127	PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 182-190.	2.8	136
128	Disparities in survival of stomach cancer among different socioeconomic groups in North-East Netherlands. <i>Cancer Epidemiology</i> , 2011, 35, 413-416.	0.8	19
129	VEGF-SPECT with <sup>111</sup> In-bevacizumab in stage III/IV melanoma patients. <i>European Journal of Cancer</i> , 2011, 47, 1595-1602.	1.3	51
130	Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 264-277.	2.0	11
131	Retrospective Denial as A Coping Method. <i>Journal of Clinical Psychology in Medical Settings</i> , 2011, 18, 65-69.	0.8	5
132	Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues. <i>Oncologist</i> , 2011, 16, 783-787.	1.9	62
133	VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. <i>Cancer Research</i> , 2011, 71, 143-153.	0.4	105
134	Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. <i>Gastric Cancer</i> , 2010, 13, 95-100.	2.7	1
135	Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets. <i>Methods in Molecular Biology</i> , 2010, 596, 15-31.	0.4	13
136	A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 10.	0.4	8
137	Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen. <i>Vaccine</i> , 2009, 28, 386-391.	1.7	1
138	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography for Monitoring Response to Sorafenib Treatment in Patients with Hepatocellular Carcinoma. <i>Oncologist</i> , 2008, 13, 734-735.	1.9	17
139	Improvement of In Vivo Transfer of Plasmid DNA in Muscle: Comparison of Electroporation versus Ultrasound. <i>Drug Delivery</i> , 2007, 14, 273-277.	2.5	21
140	Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response. <i>Acute Cardiac Care</i> , 2006, 8, 41-45.	0.2	9
141	A review on pro- and anti-angiogenic factors as targets of clinical intervention. <i>Pharmacological Research</i> , 2006, 53, 89-103.	3.1	138
142	<sup>18</sup> F-FAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. <i>Nuclear Medicine Communications</i> , 2006, 27, 25-30.	0.5	51
143	Functional Characteristics of Coronary Vasomotor Function Following Intramyocardial Gene Therapy with Naked DNA Encoding for Vascular Endothelial Growth Factor165. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2005, 12, 103-106.	1.7	5
144	Influence of p53 Status on the HSV-Tk/GCV-Induced Bystander Effect in a Panel of Human Ovarian Carcinoma Cell Lines. <i>Oncology Research</i> , 2005, 15, 151-159.	0.6	3

#	ARTICLE	IF	CITATIONS
145	Treatment of locally advanced rectal cancer. <i>Surgical Oncology</i> , 2004, 13, 137-147.	0.8	14
146	PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1437-43.	2.8	28
147	Combination of Vascular Endothelial Growth Factor (VEGF) and Thymidine Phosphorylase (TP) to Improve Angiogenic Gene Therapy. <i>Angiogenesis</i> , 2003, 6, 185-192.	3.7	5
148	Platelets and Granulocytes, in Particular the Neutrophils, Form Important Compartments for Circulating Vascular Endothelial Growth Factor. <i>Angiogenesis</i> , 2003, 6, 283-287.	3.7	442
149	Evaluation of [ <sup>18</sup> F]FHPG as PET tracer for HSVtk gene expression. <i>Nuclear Medicine and Biology</i> , 2003, 30, 651-660.	0.3	16
150	Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.. <i>Current Gene Therapy</i> , 2002, 2, 307-322.	0.9	129
151	Scintigraphic Imaging of HSVtk Gene Therapy. <i>Current Pharmaceutical Design</i> , 2002, 8, 1435-1450.	0.9	19
152	Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. <i>Angiogenesis</i> , 2001, 4, 91-102.	3.7	312
153	[ <sup>11</sup> C]FMAU and [ <sup>18</sup> F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. <i>Nuclear Medicine and Biology</i> , 2000, 27, 113-119.	0.3	67